• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Indivior PLC

    4/23/25 8:04:52 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    8-K
    false 0001625297 0001625297 2025-04-24 2025-04-24
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 24, 2025

     

     

    INDIVIOR PLC

    (Exact name of registrant as specified in its charter)

     

     

     

    England and Wales   001-37835   98-1204773

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    10710 Midlothian Turnpike Suite 125

    North Chesterfield, VA

        23235
    (Address of principal executive offices)     (Zip Code)

    Registrant’s telephone number, including area code: 804-379-1040

     

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Ordinary shares, $0.50 nominal value per share   INDV   The Nasdaq Stock Market LLC
        Indicate by check
      INDV   London Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02

    Results of Operations and Financial Condition.

    On April 24, 2025, Indivior PLC (“Indivior”) issued a press release reporting its first quarter 2025 results and posted on its website the press release and related presentation materials. The press release and related presentation materials are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

     

    Item 9.01

    Financial Statements and Exhibits.

     

    Exhibit

    No.

       Description
    99.1    Press release issued by Indivior PLC dated April 24, 2025.
    99.2    Presentation materials dated April 24, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          Indivior PLC

     Date: April 24, 2025

        By:  

    /s/ Kathryn Hudson

        Name:   Kathryn Hudson
        Title:   Company Secretary
    Get the next $INDV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    SEC Filings

    See more
    • Indivior PLC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/30/25 7:03:38 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior PLC filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/24/25 4:52:40 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Indivior PLC

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/2/25 6:06:09 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on Indivior with a new price target

      Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

      7/22/25 7:52:44 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Indivior with a new price target

      Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

      1/28/25 7:14:13 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Indivior with a new price target

      Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00

      7/23/24 6:29:18 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (NASDAQ:INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Authority; and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's  main market for listed securities, have now been cancelled with effect from 08:00 a.m. UK time today, July 25, 2025 (the "London Delisting"). Indivior continues to maintain its primary listing of Ordinary Shares on the Nasdaq Stock Market.

      7/25/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

      Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomesRICHMOND, Va., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder

      7/23/25 8:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

      RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET.  Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event beg

      7/17/25 9:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Indivior PLC

      SC 13G - INDIVIOR PLC (0001625297) (Subject)

      11/15/24 6:03:54 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Indivior PLC

      SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

      11/14/24 5:00:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Indivior PLC

      SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

      11/7/24 8:23:16 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    See more
    • Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

      RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

      7/8/25 8:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Appoints Tony Kingsley to the Board of Directors

      RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

      6/24/25 4:12:00 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Patrick Barry as Chief Commercial Officer

      Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. "Patrick is an accomplished and resp

      5/27/25 8:30:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Financials

    Live finance-specific insights

    See more
    • Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

      RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET.  Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event beg

      7/17/25 9:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circula

      6/2/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care